"Currently available assays that can make cell-by-cell measurements include traditional cytogenetic approaches, like G-banding and standard FISH. dGH can readily detect these variants, as well as multiple complex variants and potentially more gentoxic small inversions, all at high resolution and all concurrently in a single assay, making it an ideal candidate for genotoxicity testing, as well as for informing and optimizing personalized medicine strategies based on CRISPR/CAS-9 and any genome editing technology that induces intentional (or unintentional) DSBs."https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10817574/I work with researchers to create post-edit genomic structural integrity data packages that are admissible by the FDA. Interested? Let's Chat!

The focus of my research at Purdue University was to investigate how epigenetic markers affected disease phenotypes. The projects that I worked on involved in vitro CRISPR engineering of both cancer and Alzheimer's disease models.